This cell line has been shown to significantly alter the function of complex II (CII) of the mitochondrial electron transport chain and displays disruptions to SDHD that mimic clinical presentations of CII deficiency.
| Inventor | Institute |
|---|---|
| Abey Bandara | Virginia Tech |
| SKU: | 160706 |
|---|---|
| Product description: | The HEK293?SDHD cell line expresses a CRISPR/Cas9 mutated nuclear encoded subunit, SDHD, of mitochondrial complex II (succinate dehydrogenase). This cell line has been shown to significantly alter the function of complex II (CII) of the mitochondrial electron transport chain and displays disruptions to SDHD that mimic clinical presentations of CII deficiency. These cells represent a powerful model of metabolic pathologies, not only for mitochondrial disease, but also for understanding the importance of CII in developing novel therapeutics. CRISPR edited HEK293 cells.Specific disruptions in SDHD have been reported to present clinically as the following disease conditions:-Complex II deficiency-Paraganglioma |
| Alternate name: | HEK293?SDHD |
| Production details: | The cell line is currently stored at Virginia Tech. |
| Additional notes: | CRISPR edited HEK293 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provi… |
| Parental cell line: | HEK293 |
| Disease: | Mitochondrial Disease |
| Cat. #: | 160706 |
|---|---|
| Tool sub type: | Continuous |
| Unit size: | 1×10^6 cells / vial |
| Research Fields: | Cancer; Drug development; Metabolism |
| Organism: | Human |
| Model: | Knock-Out |
| Growth properties: | The mutant has been shown to grow much slower than the parental cell line. The doubling time of the mutant is also significantly slower than that of the parental line. |
| Format: | Frozen |
|---|---|
| Shipping conditions: | Dry ice |
| Growth medium: | DMEM medium supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin at 37?°C temperature and 5-6% CO2. |
| Recommended controls: | HEK293 parental line |
| References: |
Bandara et al. 2021. BMC Mol Cell Biol. 22(1):35. PMID: 34118887. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.